Outcomes by tumor subtype and treatment pattern in women with small, node-negative breast cancer: A multi-institutional study

Journal of Clinical Oncology

Volumn 32, Issue 20, 2014, Pages 2142-2150

  Vaz Luis, Ines ^a,c   Ottesen, Rebecca A ^d   Hughes, Melissa E ^a   Mamet, Rizvan ^d   Burstein, Harold J ^a   Edge, Stephen B ^f,g   Gonzalez Angulo, Ana M ^h   Moy, Beverly ^b   Rugo, Hope S ^e   Theriault, Richard L ^h   Weeks, Jane C ^a   Winer, Eric P ^a   Lin, Nancy U ^a  

^a DANA FARBER CANCER INSTITUTE   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

^c INSTITUTO DE MEDICINA MOLECULAR   (Portugal)

^d CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

^e UNIVERSITY OF CALIFORNIA   (United States)

^f ROSWELL PARK CANCER INSTITUTE   (United States)

^g BAPTIST CANCER CENTER   (United States)

^h UNIVERSITY OF TEXAS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; HORMONE RECEPTOR; TRASTUZUMAB;

ADJUVANT THERAPY; ADULT; AGED; ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER DIAGNOSIS; CANCER GRADING; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER RISK; CANCER SIZE; CANCER STAGING; CANCER SURVIVAL; COHORT ANALYSIS; COMORBIDITY; CONTROLLED STUDY; DISEASE FREE SURVIVAL; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; PROSPECTIVE STUDY; RECURRENCE FREE SURVIVAL; TUMOR VOLUME;

ADULT; AGED; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; DISEASE-FREE SURVIVAL; FEMALE; FOLLOW-UP STUDIES; HUMANS; MASTECTOMY, SEGMENTAL; MIDDLE AGED; NEOPLASM STAGING; PROGNOSIS; PROSPECTIVE STUDIES; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; TREATMENT OUTCOME; TRIPLE NEGATIVE BREAST NEOPLASMS; TUMOR MARKERS, BIOLOGICAL; UNITED STATES;

EID: 84905860749     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2013.53.1608     Document Type: Article

References (48)

1. Kennedy T, Stewart AK, Bilimoria KY, et al: Treatment trends and factors associated with survival in T1aN0 and T1bN0 breast cancer patients. Ann Surg Oncol 14:2918-2927, 2007 (Pubitemid 47460628)
2. Schootman M, Jeffe D, Reschke A, et al: The full potential of breast cancer screening use to reduce mortality has not yet been realized in the United States. Breast Cancer Res Treat 85:219-222, 2004 (Pubitemid 38987255)
3. Berry DA, Cronin KA, Plevritis SK, et al: Effect of screening and adjuvant therapy on mortality from breast cancer. N Engl J Med 353:1784-1792, 2005 (Pubitemid 41549890)
4. Hanrahan EO, Gonzalez-Angulo AM, Giordano SH, et al: Overall survival and cause-specific mortality of patients with stage T1a,bN0M0 breast carcinoma. J Clin Oncol 25:4952-4960, 2007 (Pubitemid 350220427)
5. Smart CR, Hartmann WH, Beahrs OH, et al: Insights into breast cancer screening of younger women: Evidence from the 14-year follow-up of the Breast Cancer Detection Demonstration Project. Cancer 72:1449-1456, 1993 (Pubitemid 23228012)
6. Tabár L, Fagerberg G, Day NE, et al: Breast cancer treatment and natural history: New insights from results of screening. Lancet 339:412-414, 1992
7. Fisher B, Dignam J, Tan-Chiu E, et al: Prognosis and treatment of patients with breast tumors of one centimeter or less and negative axillary lymph nodes. J Natl Cancer Inst 93:112-120, 2001 (Pubitemid 32111988)
8. Fehrenbacher L, Capra AM, Quesenberry CP Jr, et al: Distant invasive breast cancer recurrence risk in human epidermal growth factor receptor 2-positive T1a and T1b node-negative localized breast cancer diagnosed from 2000 to 2006: A cohort from an integrated health care delivery system. J Clin Oncol 32:2151-2158, 2014
9. Curigliano G, Viale G, Bagnardi V, et al: Clinical relevance of HER2 overexpression/amplification in patients with small tumor size and node-negative breast cancer. J Clin Oncol 27:5693-5699, 2009
10. Gonzalez-Angulo AM, Litton JK, Broglio KR, et al: High risk of recurrence for patients with breast cancer who have human epidermal growth factor receptor 2-positive, node-negative tumors 1 cm or smaller. J Clin Oncol 27:5700-5706, 2009
11. McArthur HL, Mahoney KM, Morris PG, et al: Adjuvant trastuzumab with chemotherapy is effective in women with small, node-negative, HER2-positive breast cancer. Cancer 117:5461-5468, 2011
12. Chia S, Norris B, Speers C, et al: Human epidermal growth factor receptor 2 overexpression as a prognostic factor in a large tissue microarray series of node-negative breast cancers. J Clin Oncol 26:5697-5704, 2008
13. Park YH, Kim ST, Cho EY, et al: A risk stratification by hormonal receptors (ER, PgR) and HER-2 status in small (< or = 1 cm) invasive breast cancer: Who might be possible candidates for adjuvant treatment? Breast Cancer Res Treat 119:653-661, 2010
14. Amar S, McCullough AE, Tan W, et al: Prognosis and outcome of small (<= 1 cm), node-negative breast cancer on the basis of hormonal and HER-2 status. Oncologist 15:1043-1049, 2010
15. Wong FY, Yip CS, Chua ET: Implications of HER2 amplification in small, node-negative breast cancers: Do Asians differ? World J Surg 36:287-294, 2012
16. Weeks JC: Outcomes assessment in the NCCN. Oncology (Williston Park) 11:137-140, 1997
17. Weeks J: Outcomes assessment in the NCCN: 1998 update: National Comprehensive Cancer Network. Oncology (Williston Park) 13:69-71, 1999
18. Niland JC: NCCN outcomes research database: Data collection via the Internet. Oncology (Williston Park) 14:100-103, 2000
19. Punglia RS, Hughes ME, Edge SB, et al: Factors associated with guideline-concordant use of radiotherapy after mastectomy in the National Comprehensive Cancer Network. Int J Radiat Oncol Biol Phys 72:1434-1440, 2008
20. Charlson ME, Pompei P, Ales KL, et al: A new method of classifying prognostic comorbidity in longitudinal studies: Development and validation. J Chronic Dis 40:373-383, 1987 (Pubitemid 17055592)
21. Katz JN, Chang LC, Sangha O, et al: Can comorbidity be measured by questionnaire rather than medical record review? Med Care 34:73-84, 1996 (Pubitemid 126433198)
22. Hudis CA, Barlow WE, Costantino JP, et al: Proposal for standardized definitions for efficacy end points in adjuvant breast cancer trials: The STEEP system. J Clin Oncol 25:2127-2132, 2007 (Pubitemid 46972801)
23. Swain SM, Tang G, Geyer CE Jr, et al: Definitive results of a phase III adjuvant trial comparing three chemotherapy regimens in women with operable, node-positive breast cancer: The NSABP B-38 trial. J Clin Oncol 31:3197-3204, 2013
24. Hassett MJ, O'Malley AJ, Pakes JR, et al: Frequency and cost of chemotherapy-related serious adverse effects in a population sample of women with breast cancer. J Natl Cancer Inst 98:1108-1117, 2006 (Pubitemid 44288785)
25. Piccart-Gebhart MJ, Procter M, Leyland-Jones B, et al: Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 353:1659-1672, 2005 (Pubitemid 41464705)
26. Romond EH, Perez EA, Bryant J, et al: Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 353:1673-1684, 2005 (Pubitemid 41464706)
27. Slamon D, Eiermann W, Robert N, et al: Adjuvant trastuzumab in HER2-positive breast cancer. N Engl J Med 365:1273-1283, 2011
28. Smith LA, Cornelius VR, Plummer CJ, et al: Cardiotoxicity of anthracycline agents for the treatment of cancer: Systematic review and meta-analysis of randomised controlled trials. BMC Cancer 10:337, 2010
29. Postma TJ, Vermorken JB, Liefting AJ, et al: Paclitaxel-induced neuropathy. Ann Oncol 6:489-494, 1995
30. Lee JJ, Swain SM: Peripheral neuropathy induced by microtubule- stabilizing agents. J Clin Oncol 24:1633-1642, 2006 (Pubitemid 46638788)
31. Morton LM, Dores GM, Tucker MA, et al: Evolving risk of therapy-related acute myeloid leukemia following cancer chemotherapy among adults in the United States, 1975-2008. Blood 121:2996-3004, 2013
32. Romond EH, Jeong JH, Rastogi P, et al: Seven-year follow-up assessment of cardiac function in NSABP B-31, a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel (ACP) with ACP plus trastuzumab as adjuvant therapy for patients with node-positive, human epidermal growth factor receptor 2-positive breast cancer. J Clin Oncol 30:3792-3799, 2012
33. Karp J, Blackford A, Visvanathan K, et al: Myelodysplastic syndrome and/or acute myelogenous leukemia (MDS and/or AML) after a breast cancer diagnosis: The National Comprehensive Cancer Network (NCCN) experience. Cancer Res 72:S3-S5, 2012 (suppl; abstr SABCS12-S3-5)
34. Perez EA, Romond EH, Suman VJ, et al: Four-year follow-up of trastuzumab plus adjuvant chemotherapy for operable human epidermal growth factor receptor 2-positive breast cancer: Joint analysis of data from NCCTG N9831 and NSABP B-31. J Clin Oncol 29:3366-3373, 2011
35. Joensuu H, Kellokumpu-Lehtinen PL, Bono P, et al: Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer. N Engl J Med 354:809-820, 2006 (Pubitemid 43290919)
36. Bowles EJ, Wellman R, Feigelson HS, et al: Risk of heart failure in breast cancer patients after anthracycline and trastuzumab treatment: A retrospective cohort study. J Natl Cancer Inst 104:1293-1305, 2012
37. Chen J, Long JB, Hurria A, et al: Incidence of heart failure or cardiomyopathy after adjuvant trastuzumab therapy for breast cancer. J Am Coll Cardiol 60:2504-2512, 2012
38. Vaz-Luis I, Keating NL, Lin NU, et al: Duration and toxicity of adjuvant trastuzumab in older patients with early-stage breast cancer: A population-based study. J Clin Oncol 32:927-934, 2013
39. Paik S, Shak S, Tang G, et al: A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med 351:2817-2826, 2004 (Pubitemid 40051905)
40. Paik S, Tang G, Shak S, et al: Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer. J Clin Oncol 24:3726-3734, 2006 (Pubitemid 46622311)
41. National Comprehensive Cancer Network: Breast Cancer, version 3.2014.http://www.nccn.org/professionals/physician-gls/pdf/breast.pdf
42. Vaz-Luis I, Ottesen RA, Hughes ME, et al: Impact of hormone receptor status on patterns of recurrence and clinical outcomes among patients with human epidermal growth factor-2-positive breast cancer in the National Comprehensive Cancer Network: A prospective cohort study. Breast Cancer Res 14:R129, 2012
43. Untch M, Gelber RD, Jackisch C, et al: Estimating the magnitude of trastuzumab effects within patient subgroups in the HERA trial. Ann Oncol 19:1090-1096, 2008 (Pubitemid 351796334)
44. Adjuvant! Online: Decision making tools for health care professionals. http://www.adjuvantonline.com/index.jsp
45. Pritt B, Tessitore JJ, Weaver DL, et al: The effect of tissue fixation and processing on breast cancer size. Hum Pathol 36:756-760, 2005 (Pubitemid 41112030)
46. Provencher L, Diorio C, Hogue JC, et al: Does breast cancer tumor size really matter that much? Breast 21:682-685, 2012
47. Rosen PR, Groshen S, Saigo PE, et al: A long-term follow-up study of survival in stage I (T1N0M0) and stage II (T1N1M0) breast carcinoma. J Clin Oncol 7:355-366, 1989
48. Early Breast Cancer Trialists' Collaborative Group (EBCTCG): Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: An overview of the randomised trials. Lancet 365:1687-1717, 2005